Stephen Uden - 06 Feb 2023 Form 4 Insider Report for Rallybio Corp (RLYB)

Role
Chief Operating Officer & Chief Scientific Officer
Signature
/s/ Michael Greco, Attorney-in-Fact
Issuer symbol
RLYB
Transactions as of
06 Feb 2023
Transactions value $
$0
Form type
4
Filing time
06 Feb 2023, 16:42:58 UTC
Previous filing
09 Feb 2022
Next filing
16 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLYB Option (Right to Buy) Award $0 +214K $0.00 214K 06 Feb 2023 Common Stock 214K $6.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 6, 2027.

Remarks:

Chief Operating Officer & Chief Scientific Officer